Opportunity Information: Apply for PAR 13 344
Apply for PAR 13 344
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Sep 4, 2013 and posted on Sep 4, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) State governments County governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses City or township governments Public and State controlled institutions of higher education Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Small businesses Independent school districts Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR 13 344, titled "Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R03)," is a discretionary grant program designed to support early-stage, short-duration research projects that tackle practical problems in making medicines work better for children. Its central focus is on improving how drugs are formulated and delivered across pediatric age groups, recognizing that infants, toddlers, school-age children, and adolescents can have very different needs in terms of dosing, safety, usability, and acceptance. The announcement emphasizes that pediatric medicines are not simply smaller versions of adult medicines, and it aims to fund targeted research that helps close gaps in child-appropriate dosage forms and delivery technologies.
The purpose of the FOA is twofold. First, it seeks research that advances the development and acceptability of pediatric drug formulations, meaning dosage forms that children can realistically take as intended and caregivers can administer correctly. This includes work that addresses palatability, swallowability, dosing flexibility, stability, and age-appropriate excipients, as well as the real-world factors that influence whether a formulation is likely to be used correctly in clinical or home settings. Second, it explicitly encourages the creation and testing of novel pediatric drug delivery systems. That could involve new ways of getting medicines into the body or improving the performance and usability of existing routes of administration, with the goal of making delivery safer, more reliable, and more suitable for children.
A key theme of the announcement is innovation in approach. Applicants are encouraged to explore concepts that are new to pediatric formulation science and to apply newly developed techniques that outperform the standard methods used in the field at the time. In practical terms, the FOA signals interest in projects that go beyond incremental adjustments and instead introduce improved technologies, evaluation methods, or formulation strategies that can better handle pediatric constraints such as limited dosing volumes, taste sensitivity, variable ability to swallow solids, and the need for accurate dose measurement across a wide range of body weights.
This opportunity uses the R03 mechanism, which is generally intended for small research projects or pilot studies. The listed award ceiling is $50,000, and the program does not require cost sharing or matching funds. The funding activity category is Health, and it is associated with CFDA number 93.865 (Child Health and Human Development Extramural Research), reflecting its alignment with child health priorities. The sponsoring agency is the National Institutes of Health.
Eligibility is broad and includes many types of organizations. Domestic applicants can include public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (including small businesses), and a wide range of government entities such as state, county, city or township governments, special district governments, and independent school districts, along with public housing authorities and Indian housing authorities. Tribal eligibility includes federally recognized tribal governments and other tribal organizations. The FOA also highlights eligibility for various mission-focused and community-based institutions, including HBCUs, Hispanic-serving institutions, AANAPISIS institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and faith-based or community-based organizations. Importantly, foreign participation is allowed: non-U.S. entities (foreign organizations and foreign institutions) may apply, non-U.S. components of U.S. organizations are eligible, and foreign components as defined by NIH policy are permitted.
In terms of timing and status, the opportunity was posted and created on September 4, 2013, with an original and current closing date of September 7, 2016. The archive date is October 8, 2016, indicating the solicitation is no longer active, but it remains a useful reference for understanding NIH priorities and the types of pediatric formulation and delivery work NIH has sought to stimulate through small-grant mechanisms.
For reference and official details, the full announcement was available through the NIH Grants Guide at the link provided in the source data. Technical issues accessing or linking to the announcement were directed to the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
FAQs: NIH PAR-13-344 - Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R03)
What is PAR-13-344?
PAR-13-344 is a National Institutes of Health (NIH) funding opportunity announcement titled "Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R03)." It supports short-duration, early-stage research projects focused on improving how medicines are formulated and delivered for children across pediatric age groups.
What is the main goal of this funding opportunity?
The central goal is to fund practical, targeted research that helps close gaps in child-appropriate dosage forms and drug delivery technologies. The announcement emphasizes that pediatric medicines are not simply smaller versions of adult medicines and that children have distinct needs related to dosing, safety, usability, and acceptance.
What types of research does this FOA prioritize?
The FOA prioritizes two broad areas: (1) research that advances the development and acceptability of pediatric drug formulations (dosage forms children can realistically take as intended), and (2) the creation and testing of novel pediatric drug delivery systems that improve safety, reliability, and suitability for children.
What does "pediatric drug formulation acceptability" include?
Based on the FOA description, acceptability-focused work can include factors such as palatability, swallowability, dosing flexibility, stability, age-appropriate excipients, and real-world considerations that affect whether caregivers and patients can administer and use the medicine correctly in clinical or home settings.
What are examples of pediatric constraints this FOA is concerned with?
The FOA highlights pediatric constraints including limited dosing volumes, taste sensitivity, variable ability to swallow solid dosage forms, and the need for accurate dose measurement across a wide range of body weights.
What does the FOA mean by "novel pediatric drug delivery systems"?
The FOA encourages new ways of getting medicines into the body or improving existing routes of administration to make delivery safer, more reliable, and more suitable for children. The emphasis is on improved performance and usability in pediatric populations.
Is the program looking for incremental improvements or innovation?
A key theme is innovation in approach. Applicants are encouraged to explore concepts new to pediatric formulation science and apply newly developed techniques that outperform standard methods used in the field at the time, rather than limiting projects to incremental adjustments.
What grant mechanism does PAR-13-344 use?
This opportunity uses the NIH R03 mechanism, which is generally intended for small research projects or pilot studies and supports early-stage, short-duration research.
What is the maximum award amount listed for this opportunity?
The listed award ceiling is $50,000.
Is cost sharing or matching required?
No. The program does not require cost sharing or matching funds.
What is the funding activity category?
The funding activity category is Health.
What CFDA number is associated with this opportunity?
The FOA is associated with CFDA number 93.865, described as Child Health and Human Development Extramural Research.
Which agency sponsors this funding opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
Who is eligible to apply?
Eligibility is broad. Domestic applicants may include public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses), and many government entities such as state, county, city or township governments, special district governments, independent school districts, public housing authorities, and Indian housing authorities.
Are tribal governments and tribal organizations eligible?
Yes. The FOA includes federally recognized tribal governments and other tribal organizations among eligible applicants.
Are specific mission-focused or community-based institutions eligible?
Yes. The FOA highlights eligibility for organizations such as HBCUs, Hispanic-serving institutions, AANAPISIS institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, as well as faith-based or community-based organizations.
Is foreign participation allowed?
Yes. Foreign participation is allowed. Non-U.S. entities (foreign organizations and foreign institutions) may apply, non-U.S. components of U.S. organizations are eligible, and foreign components as defined by NIH policy are permitted.
When was this opportunity posted and when did it close?
The opportunity was posted and created on September 4, 2013. The original and current closing date listed is September 7, 2016.
Is PAR-13-344 still active?
No. The archive date is October 8, 2016, indicating the solicitation is no longer active. It remains useful as a reference for NIH priorities and the types of pediatric formulation and delivery projects NIH has supported through small-grant mechanisms.
Where could applicants find the official announcement?
The full announcement was available through the NIH Grants Guide at the link provided in the source data.
Who should be contacted for technical issues accessing the announcement?
Technical issues accessing or linking to the announcement were directed to the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: National Park Service Concept Plan for Intermountain Region Mobile Exhibit
Previous opportunity: Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 344
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 344) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R43) Apply for PAR 13 345 Funding Number: PAR 13 345 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems STTR (R41) Apply for PAR 13 346 Funding Number: PAR 13 346 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Sustained Release of Antivirals for Treatment and Prevention of HIV (SRATP) (R01) Apply for PAR 13 349 Funding Number: PAR 13 349 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Enhancing the Capacity for Biomedical Research on Tuberculosis for HIV infected Mothers and Children in India (R01) Apply for RFA HD 14 025 Funding Number: RFA HD 14 025 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $350,000 |
| Developmental Origins of Health and Disease (DOHaD) Epigenetic Modification in Gametogenesis and Transgenerational Inheritance (R01) Apply for PAR 13 385 Funding Number: PAR 13 385 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $250,000 |
| Female Contraceptive Development Program (U01) Apply for RFA HD 14 024 Funding Number: RFA HD 14 024 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $250,000 |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44) Apply for RFA HD 14 031 Funding Number: RFA HD 14 031 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01) Apply for PAR 13 389 Funding Number: PAR 13 389 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (STTR) (R41/R42) Apply for RFA HD 14 032 Funding Number: RFA HD 14 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Centers for Collaborative Research in Fragile X (U54) Apply for RFA HD 14 033 Funding Number: RFA HD 14 033 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Juvenile Protective Factors and Their Effects on Aging (R03) Apply for PAR 14 022 Funding Number: PAR 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| U.S South Africa Program for Collaborative Biomedical Research (U01) Apply for RFA AI 14 018 Funding Number: RFA AI 14 018 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $225,000 |
| Data Sharing for Demographic Research Infrastructure Program (U24) Apply for RFA HD 14 015 Funding Number: RFA HD 14 015 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Intellectual and Developmental Disabilities Research Centers 2014 (U54) Apply for RFA HD 14 012 Funding Number: RFA HD 14 012 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Population Dynamics Centers Research Infrastructure (P2C) Apply for RFA HD 14 016 Funding Number: RFA HD 14 016 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Data Coordinating Center for the Collaborative Pediatric Critical Care Research Network (U01) Apply for RFA HD 14 020 Funding Number: RFA HD 14 020 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Collaborative Pediatric Critical Care Research Network (UG1) Apply for RFA HD 14 022 Funding Number: RFA HD 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Sustained Release for Antiretroviral Treatment or Prevention (SRATP) of HIV Infection (UM1) Apply for RFA AI 14 008 Funding Number: RFA AI 14 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R43) Apply for RFA HD 15 008 Funding Number: RFA HD 15 008 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Isolation, Purification, and Synthesis of Human Milk Oligosaccharides with Antimicrobial Activity (R41) Apply for RFA HD 15 007 Funding Number: RFA HD 15 007 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 344", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.